Clinical Trial Update: A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) [Phase 2]

View source ↗

Summary

Phase 2 safety-run-in update for weekly tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Tisotumab Vedotin (tisotumab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-06